1. Quality improvement initiative to improve inpatient outcomes for Neonatal Abstinence Syndrome
- Author
-
Fnu Nikita, Bonny L. Whalen, Crystal D. Alvarez, Robin Humphreys, Matthew Grossman, Elisha M. Wachman, Barbara L. Philipp, Camilla Farrell, Kelley Saia, Susan Minear, Jennifer Driscoll, Ahmad Khattab, Angela Nolin, Hira Shrestha, J. F. Burke, Karan Barry, Donna Stickney, Ginny Combs, Elizabeth Hutton, and Davida M. Schiff
- Subjects
Adult ,Male ,medicine.medical_specialty ,Quality management ,MEDLINE ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,030225 pediatrics ,Health care ,medicine ,Opiate Substitution Treatment ,Humans ,030212 general & internal medicine ,Hospital Costs ,Adverse effect ,Quality Indicators, Health Care ,Inpatients ,business.industry ,Infant, Newborn ,Obstetrics and Gynecology ,Length of Stay ,medicine.disease ,Quality Improvement ,United States ,Opioid ,Prenatal Exposure Delayed Effects ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Female ,business ,Neonatal Abstinence Syndrome ,Methadone ,medicine.drug - Abstract
To improve Neonatal Abstinence Syndrome (NAS) inpatient outcomes through a comprehensive quality improvement (QI) program. Inclusion criteria were opioid-exposed infants ≥36 weeks. QI methodology including stakeholder interviews and plan-do-study-act (PDSA) cycles were utilized. We compared pre- and post-intervention NAS outcomes after a QI initiative that included: A non-pharmacologic care bundle, function-based assessments consisting of symptom prioritization and then the “Eat, Sleep, Console” (ESC) Tool; and a switch to methadone for pharmacologic treatment. Pharmacologic treatment decreased from 87.1 to 40.0%; adjunctive agent use from 33.6 to 2.4%; hospitalization length from a mean 17.4 to 11.3 days, and opioid treatment days from 16.2 to 12.7 (p
- Published
- 2018